Amneal Pharmaceuticals Inc.
AMRX | NASDAQ
$19.51
-$0.65 (-3.22%)
Sep 22, 2026, 10:36 AM ET · Market open
Market Data
Market Cap $6.44B
Enterprise Value $9.1B
Beta 1.24
Average Volume 1.89M
Shares Outstanding (Diluted) 328.1M
Shares Change YoY 1.78%
Institutional Ownership 50.91%
Exchange NASDAQ
ISIN US03168L1052
Price Performance
Price Change 1M 12.9%
Price Change 3M 21.0%
Price Change 6M 64.4%
Price Change YTD 59.2%
Price Change 1Y 101.6%
Price Change 3Y 381.1%
Price Change 5Y 279.7%
1M CAGR (ann.) 11.1%
1Y CAGR (ann.) 105.5%
5Y CAGR (ann.) 31.6%
All-Time CAGR 8.5%
Valuation
PE Ratio 41.14
Forward PE 16.65
PEG Ratio 0.01
Forward PEG 2.36
PS Ratio 2.06
Forward PS 1.90
PB Ratio 194.94
P/FCF Ratio 43.51
P/Adj. FCF Ratio 53.14
P/OCF Ratio 32.00
EV/Sales 2.92
EV/EBIT 30.08
EV/EBITDA 20.33
EV/FCF 61.52
Earnings Yield 2.4%
FCF Yield 2.3%
Adj. FCF Yield 1.9%
Financial Health
Net Debt $2.54B
Total Debt $2.79B
Cash & Short-Term Investments $127.64M
Total Assets $3.78B
Current Ratio 2.20
Quick Ratio 1.44
Debt / Equity Ratio 84.54
Debt / EBITDA 6.23
Debt / FCF 18.87
OCF / Debt 0.08
Interest Coverage 1.77
Altman Z-Score 2.46
Piotroski F-Score 6
Margins & Profitability
Gross Profit Margin 39.3%
Operating Profit Margin 7.9%
EBITDA Margin 20.9%
Net Profit Margin 5.0%
FCF Margin 4.8%
Adj. FCF Margin 3.9%
SBC / Revenue 0.9%
SBC Impact (per share) -18.1%
Returns
Return on Assets 4.2%
Return on Equity -326.8%
Return on Invested Capital 13.4%
Return on Capital Employed 13.9%
Return on Tangible Assets 6.1%
Historical Growth (CAGR)
Revenue CAGR 3Y 10.5%
Revenue CAGR 5Y 8.7%
Revenue CAGR 10Y 13.3%
EPS CAGR 3Y 1349.3%
EPS CAGR 5Y 52.9%
EPS CAGR 10Y -13.1%
FCF CAGR 3Y 0.5%
FCF CAGR 5Y -4.0%
FCF CAGR 10Y 16.7%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 17
EPS Growth Next 3Y 55.1%
Revenue Growth Next 3Y 12.2%
Earnings Date Oct 28, 2026
EPS Estimate (next Q) $0.23
EPS Growth Est (next Q) 35.3%
Revenue Est (next Q) $812.86M
Revenue Growth Est (next Q) 3.6%
Fair Value Estimates
Graham Number $2.02
Graham Upside -90.0%
Lynch Fair Value $12.25
Lynch Upside -39.2%
Price Target $22.25
Price Target Upside 10.4%
Cash Flow
Operating Cash Flow $220.04M
Free Cash Flow $147.96M
Adj. Free Cash Flow $121.15M
FCF Per Share $0.26
OCF Per Share $0.63
OCF/S Ratio 6.4%
Income Statement
Revenue $3.12B
Gross Profit $1.23B
Operating Income $246.62M
EBITDA $447.79M
Net Income $157.6M
EPS (Diluted) $0.49
Revenue / Employee $358.34K
Profit / Employee $18.12K
Employees 8,700
Add to Watchlist
Select watchlists to add or remove AMRX